Supernus Pharmaceuticals (SUPN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Supernus Pharmaceuticals

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$42.00-0.92(-0.02%)Market closed

Market Cap

$2.44B

P/S

2.9x

P/B

2.4x

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (6/25).

Profitability6/25

Growth14/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality14/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 27.4x5y range 17.5x – 1201.9x

Currently near its 15-quarter median.

P/S · 2.9x5y range 2.3x – 4.0x

Currently near its 20-quarter median.

P/B · 2.4x5y range 1.5x – 2.7x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 276.7% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Share Dilution

Red Flag

Shares outstanding increased 5.3% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $2.44B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $830.44M
Q. Revenue: $219.06M
TTM EBITDA: $-28.76M
TTM Op. Income: $-130.46M
Q. Op. Income: $-57.96M
TTM Net Income: $-109.89M
Q. Net Income: $-58.37M
EPS: $-1.01
Shares Out.: $58.07M

$830.44M in TTM revenue grew 24.9% YoY, reaching $219.06M last quarter. TTM EBITDA of $-28.76M and TTM operating income of $-130.46M show growth is flowing through to the bottom line. However, net income is negative at $109.89M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 84.6%
EBITDA Margin: -14.7%
Op. Margin: -26.5%
Net Margin: -26.6%

Op. margin of -26.5% is down 33.8% YoY — costs are rising relative to revenue. Net margin at -26.6% and gross margin of 84.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.9x
P/B Ratio: 2.4x

P/S of 2.9x and P/B of 2.4x. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.43B
Cash: $179.95M
Long-Term Debt: N/A
Book Value: $1.03B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-4.81M
TTM Free Cash Flow: $18.79M
FCF Margin: 2.3%
FCF / Net Income: -0.2

TTM FCF of $18.79M on $-4.81M in operating cash flow. The FCF / Net Income ratio of -0.2x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 90% — a weakening trend.